[go: up one dir, main page]

PL368322A1 - Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity - Google Patents

Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity

Info

Publication number
PL368322A1
PL368322A1 PL02368322A PL36832202A PL368322A1 PL 368322 A1 PL368322 A1 PL 368322A1 PL 02368322 A PL02368322 A PL 02368322A PL 36832202 A PL36832202 A PL 36832202A PL 368322 A1 PL368322 A1 PL 368322A1
Authority
PL
Poland
Prior art keywords
tyrosine kinase
kinase activity
receptor tyrosine
flt3 receptor
inhibitors
Prior art date
Application number
PL02368322A
Other languages
Polish (pl)
Other versions
PL211461B1 (en
Inventor
James Douglas Griffin
Paul William Manley
Original Assignee
Novartis Ag
Dana-Farber Cancer Institute Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26991080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL368322(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Dana-Farber Cancer Institute Inc. filed Critical Novartis Ag
Publication of PL368322A1 publication Critical patent/PL368322A1/en
Publication of PL211461B1 publication Critical patent/PL211461B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)

Abstract

The present invention relates to the use of staurosporines derivatives for the preparation of a drug for the treatment of diseases involving deregulated FLT3 receptor tyrosine kinase activity, especially for the curative and/or prophylactic treatment of leukemias and myelodysplastic syndromes, and to a method of treating diseases involving deregulated FLT3 receptor tyrosine kinase activity.
PL368322A 2001-10-30 2002-10-29 Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity PL211461B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33903101P 2001-10-30 2001-10-30
US33818501P 2001-12-07 2001-12-07

Publications (2)

Publication Number Publication Date
PL368322A1 true PL368322A1 (en) 2005-03-21
PL211461B1 PL211461B1 (en) 2012-05-31

Family

ID=26991080

Family Applications (1)

Application Number Title Priority Date Filing Date
PL368322A PL211461B1 (en) 2001-10-30 2002-10-29 Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity

Country Status (25)

Country Link
US (3) US7973031B2 (en)
EP (1) EP1441737B1 (en)
JP (1) JP4959918B2 (en)
KR (2) KR20090087139A (en)
CN (2) CN1582150B (en)
AT (1) ATE335490T1 (en)
AU (1) AU2006249245B2 (en)
BR (1) BRPI0213739B8 (en)
CA (1) CA2462657C (en)
CY (1) CY1106199T1 (en)
DE (1) DE60213842T2 (en)
DK (1) DK1441737T3 (en)
ES (1) ES2269793T3 (en)
FR (1) FR18C1012I2 (en)
HU (1) HU230798B1 (en)
IL (2) IL161156A0 (en)
MX (1) MXPA04004137A (en)
NO (1) NO335685B1 (en)
NZ (1) NZ532136A (en)
PL (1) PL211461B1 (en)
PT (1) PT1441737E (en)
RU (1) RU2337692C3 (en)
TW (1) TWI302836B (en)
WO (1) WO2003037347A1 (en)
ZA (1) ZA200402498B (en)

Families Citing this family (216)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
WO2005011598A2 (en) * 2003-07-31 2005-02-10 University Of South Florida Leukemia treatment method and composition
AU2004262927B2 (en) * 2003-08-08 2008-05-22 Novartis Ag Combinations comprising staurosporines
JP2007523827A (en) 2003-08-25 2007-08-23 ダナ−ファーバー　キャンサー　インスティテュート，インコーポレイテッド Method for treating acute lymphoblastic leukemia with mixed leukemia gene rearrangement
EP1684762A4 (en) 2003-11-13 2009-06-17 Ambit Biosciences Corp Urea derivatives as kinase modulators
WO2005053704A1 (en) * 2003-12-01 2005-06-16 Novartis Ag Method for predicting drug responsiveness in myeloid neoplasms
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
CA2574150C (en) * 2004-07-19 2018-02-27 The Johns Hopkins University Flt3 inhibitors for immune suppression
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
MX2007006204A (en) * 2004-11-24 2007-06-20 Novartis Ag Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors.
GB0426821D0 (en) * 2004-12-07 2005-01-12 Novartis Ag Organic compounds
EP1879573B1 (en) 2005-05-10 2012-12-19 Incyte Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
WO2007010013A2 (en) * 2005-07-20 2007-01-25 Novartis Ag Combination comprising a pyrimidylaminobenzamides and a flt-3 inhibitor for treating proliferative diseases
EP1926735A1 (en) 2005-09-22 2008-06-04 Incyte Corporation Tetracyclic inhibitors of janus kinases
BRPI0617489A2 (en) 2005-10-18 2011-07-26 Janssen Pharmaceutica Nv compounds, composition and use of said compounds to inhibit flt3 kinase
GB0522932D0 (en) * 2005-11-10 2005-12-21 Univ Southampton PKC412 in treatment of atypical chronic myeloid leukemia
EP1951255A1 (en) * 2005-11-14 2008-08-06 Universität Zürich Staurosporine derivatives for use in alveolar rhabdomyosarcoma
PT2455382T (en) 2005-12-13 2017-01-31 Incyte Holdings Corp PYRIDOLES [2,3-B] PYRIDINES AND PYRROLE [2,3-B] PYRIMIDINES SUBSTITUTED BY HETEROARYLO AS JANUS KINASES INHIBITORS
JP5331680B2 (en) 2006-04-20 2013-10-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Inhibitors of c-fms kinase
PT2021335E (en) 2006-04-20 2011-07-25 Janssen Pharmaceutica Nv Heterocyclic compounds as inhibitors of c-fms kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
GB0612542D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Combinations comprising staurosporines
WO2008079965A1 (en) 2006-12-22 2008-07-03 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
CL2008001709A1 (en) 2007-06-13 2008-11-03 Incyte Corp Compounds derived from pyrrolo [2,3-b] pyrimidine, jak kinase modulators; pharmaceutical composition; and use in the treatment of diseases such as cancer, psoriasis, rheumatoid arthritis, among others.
ES2903444T3 (en) 2007-06-13 2022-04-01 Incyte Holdings Corp Use of Janus(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile kinase inhibitor salts
JO3240B1 (en) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv Inhibitors of c-fms Kinase
JP5480813B2 (en) 2007-11-16 2014-04-23 インサイト・コーポレイション Substituted heterocycles as JANUS kinase inhibitors
SI2288610T1 (en) 2008-03-11 2016-11-30 Incyte Holdings Corporation Azetidine and cyclobutane derivatives as jak inhibitors
US8871753B2 (en) 2008-04-24 2014-10-28 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
MY171866A (en) 2008-07-08 2019-11-05 Incyte Holdings Corp 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
CL2009001884A1 (en) 2008-10-02 2010-05-14 Incyte Holdings Corp Use of 3-cyclopentyl-3- [4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl) -1h-pyrazol-1-yl) propanonitrile, janus kinase inhibitor, and use of a composition that understands it for the treatment of dry eye.
WO2010085597A1 (en) 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
TW201100429A (en) 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2010135621A1 (en) 2009-05-22 2010-11-25 Incyte Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
CN104945420A (en) 2009-06-29 2015-09-30 因塞特公司 Pyrimidinones as PI3K inhibitors
AR078012A1 (en) 2009-09-01 2011-10-05 Incyte Corp HETEROCICLIC DERIVATIVES OF PIRAZOL-4-IL-PIRROLO (2,3-D) PYRIMIDINS AS INHIBITORS OF THE QUANASA JANUS
CN105541847B (en) 2009-10-09 2019-08-16 因西特控股公司 The hydroxy derivatives, ketone group derivative and glucuronide of 3- (4- (7H- pyrrolo- [2,3-d] pyrimidine-4-yl) -1H- pyrazol-1-yl) -3- cyclopenta propionitrile
EP2327706A1 (en) * 2009-11-30 2011-06-01 Novartis AG Polymorphous forms III and IV of N-benzoyl-staurosporine
US8680108B2 (en) 2009-12-18 2014-03-25 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
EP2521782B1 (en) 2010-01-05 2019-04-10 INSERM - Institut National de la Santé et de la Recherche Médicale Flt3 receptor antagonists for the treatment or the prevention of pain disorders
KR101750125B1 (en) 2010-01-12 2017-06-22 에이비 사이언스 Thiazole and oxazole kinase inhibitors
EP2536729A1 (en) 2010-02-18 2012-12-26 Incyte Corporation Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
TWI592413B (en) 2010-03-10 2017-07-21 英塞特公司 Piperidin-4-yl azetidine derivatives as jak1 inhibitors
CA2796311A1 (en) 2010-04-14 2011-10-20 Incyte Corporation Fused derivatives as pi3k.delta. inhibitors
UA111588C2 (en) 2010-05-21 2016-05-25 Інсайт Холдінгс Корпорейшн JAK INHIBITOR COMPOSITION FOR LOCAL APPLICATION
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
WO2012068450A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
EP2640725B1 (en) 2010-11-19 2015-01-07 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
WO2012087881A1 (en) 2010-12-20 2012-06-28 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
CA2827673C (en) 2011-02-18 2020-10-27 Novartis Pharma Ag Mtor/jak inhibitor combination therapy
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
AU2012273164B2 (en) 2011-06-20 2015-05-28 Incyte Holdings Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
CA2844507A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag Jak pi3k/mtor combination therapy
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
TWI717002B (en) 2011-09-02 2021-01-21 美商英塞特控股公司 Heterocyclylamines as pi3k inhibitors
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
AR090548A1 (en) 2012-04-02 2014-11-19 Incyte Corp BICYCLIC AZAHETEROCICLOBENCILAMINS AS PI3K INHIBITORS
EP2841566B1 (en) * 2012-04-24 2019-03-13 International Stem Cell Corporation Derivation of neural stem cells and dopaminergic neurons from human pluripotent stem cells
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
ES2984771T3 (en) 2012-06-13 2024-10-31 Incyte Holdings Corp Substituted tricyclic compounds as FGFR inhibitors
JOP20180012A1 (en) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv Sulfonylation process using nonafluorobutanesulfonyl fluoride
IN2015DN00659A (en) 2012-08-07 2015-06-26 Janssen Pharmaceutica Nv
JP6407504B2 (en) 2012-09-21 2018-10-17 アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Method for inhibiting constitutively active phosphorylated FLT3 kinase
CN107936039A (en) 2012-11-01 2018-04-20 因赛特公司 Tricyclic condensed thiophene derivant as JAK inhibitor
ES2880814T3 (en) 2012-11-15 2021-11-25 Incyte Holdings Corp Ruxolitinib Sustained Release Dosage Forms
BR112015016282A2 (en) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanib for treatment of mutated flt3 proliferative disorders
TWI841376B (en) 2013-03-01 2024-05-01 美商英塞特控股公司 USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS
CR20190518A (en) 2013-03-06 2020-01-10 Incyte Corp Processes and intermediates for making a jak inhibitor
ES2657451T3 (en) 2013-04-19 2018-03-05 Incyte Holdings Corporation Bicyclic heterocyclics as FGFR inhibitors
BR112015028501B8 (en) 2013-05-17 2023-01-24 Incyte Corp BIPYRAZOLE DERIVATIVE COMPOUNDS, THEIR SALTS, COMPOSITION COMPRISING THE COMPOUND OR THE SALT, METHOD FOR IN VITRO INHIBITION OF A JAK1 ACTIVITY, AND PROCESS FOR PREPARING PHOSPHORIC ACID SALT
KR20160045081A (en) 2013-08-07 2016-04-26 인사이트 코포레이션 Sustained release dosage forms for a jak1 inhibitor
CN105555313A (en) 2013-08-20 2016-05-04 因赛特公司 Survival benefit in patients with solid tumors with elevated c-reactive protein levels
US10463658B2 (en) 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody Molecules of PD-1 and Their Uses
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
WO2015131031A1 (en) 2014-02-28 2015-09-03 Incyte Corporation Jak1 inhibitors for the treatment of myelodysplastic syndromes
EA201691765A1 (en) 2014-03-14 2016-12-30 Новартис Аг ANTIBODY MOLECULES AGAINST LAG-3 AND THEIR APPLICATIONS
UA119767C2 (en) 2014-04-08 2019-08-12 Інсайт Корпорейшн Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
TW201625643A (en) 2014-04-30 2016-07-16 英塞特公司 Processes of preparing a JAK1 inhibitor and new forms thereto
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
AU2015295288B2 (en) 2014-07-31 2019-10-31 Centre National De La Recherche Scientifique (Cnrs) FLT3 receptor antagonists
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
KR102513870B1 (en) 2014-10-14 2023-03-23 노파르티스 아게 Antibody molecules to pd-l1 and uses thereof
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
CN107438607B (en) 2015-02-20 2021-02-05 因赛特公司 Bicyclic heterocycles as FGFR inhibitors
HRP20210036T1 (en) 2015-02-27 2021-03-05 Incyte Corporation Salts of pi3k inhibitor and processes for their preparation
JP6692826B2 (en) 2015-03-10 2020-05-13 アドゥロ バイオテック，インク． Compositions and methods for activation of "interferon gene stimulator" dependent signaling
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US20160362424A1 (en) 2015-05-11 2016-12-15 Incyte Corporation Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
LT3317301T (en) 2015-07-29 2021-07-26 Novartis Ag Combination therapies comprising antibody molecules to lag-3
HRP20220436T1 (en) 2015-11-03 2022-05-27 Janssen Biotech, Inc. ANTIBODIES SPECIFICALLY BINDING TO PD-1 AND THEIR USES
US10065963B2 (en) 2015-11-06 2018-09-04 Incyte Corporation Heterocyclic compounds as PI3K-γ inhibitors
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
EP3792256B1 (en) 2016-01-05 2024-10-23 Incyte Corporation Pyridine compounds as pi3k-gamma inhibitors
CN110218206B (en) * 2016-06-01 2022-03-04 中国海洋大学 Bisindolemaleimide derivatives and preparation methods and uses thereof
EP3254698A1 (en) 2016-06-08 2017-12-13 Universite De Montpellier Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
US10138248B2 (en) 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CN108778276A (en) 2016-11-02 2018-11-09 安罗格制药有限责任公司 Ke Lailani for treating FLT3 saltant type proliferative disorder related mutations
UY37695A (en) 2017-04-28 2018-11-30 Novartis Ag BIS 2’-5’-RR- (3’F-A) (3’F-A) CYCLE DINUCLEOTIDE COMPOUND AND USES OF THE SAME
CN111093640A (en) 2017-05-17 2020-05-01 国家健康与医学研究院 FLT3 inhibitors for improved opioid pain treatment
WO2018217766A1 (en) 2017-05-22 2018-11-29 Whitehead Institute For Biomedical Research Kcc2 expression enhancing compounds and uses thereof
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
CN107417743B (en) * 2017-06-15 2020-07-21 杭州科兴生物化工有限公司 Staurosporine aldehyde group substituted derivative and preparation method and application thereof
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019057649A1 (en) 2017-09-19 2019-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia
CN118063470A (en) 2017-10-18 2024-05-24 因赛特公司 Condensed imidazole derivatives substituted with tertiary hydroxyl groups as PI 3K-gamma inhibitors
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US11306079B2 (en) 2017-12-21 2022-04-19 Incyte Corporation 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
AU2019213665B2 (en) 2018-01-30 2024-06-13 Incyte Corporation Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
CN118557580A (en) 2018-02-16 2024-08-30 因赛特公司 JAK1 pathway inhibitors for the treatment of cytokine-related disorders
TWI877770B (en) 2018-02-27 2025-03-21 美商英塞特公司 Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
KR20250103804A (en) 2018-03-08 2025-07-07 인사이트 코포레이션 AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
SG11202009441PA (en) 2018-03-30 2020-10-29 Incyte Corp Treatment of hidradenitis suppurativa using jak inhibitors
WO2019191679A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Biomarkers for inflammatory skin disease
US11220510B2 (en) 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
FI3788047T3 (en) 2018-05-04 2024-11-02 Incyte Corp SOLID FORM OF FGFT INHIBITOR AND METHODS FOR THEIR PREPARATION
JP7568512B2 (en) 2018-05-04 2024-10-16 インサイト・コーポレイション Salt of FGFR inhibitor
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
CA3101368A1 (en) 2018-05-25 2019-11-28 Incyte Corporation Tricyclic heterocyclic compounds as sting activators
TWI869346B (en) 2018-05-30 2025-01-11 瑞士商諾華公司 Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
MA52761A (en) 2018-06-01 2021-04-14 Incyte Corp DOSAGE REGIMEN FOR THE TREATMENT OF PI3K-RELATED DISORDERS
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
CR20240054A (en) 2018-07-05 2024-02-26 Incyte Corp FUSED PYRAZINE DERIVATIVES AS A2A/A2B INHIBITORS (Div. 2021-71)
WO2020028565A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Tricyclic heteraryl compounds as sting activators
US10875872B2 (en) 2018-07-31 2020-12-29 Incyte Corporation Heteroaryl amide compounds as sting activators
CR20250050A (en) 2018-09-05 2025-03-19 Incyte Corp Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020093011A1 (en) 2018-11-01 2020-05-07 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US11078204B2 (en) 2018-11-13 2021-08-03 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
US11161838B2 (en) 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
US11396502B2 (en) 2018-11-13 2022-07-26 Incyte Corporation Substituted heterocyclic derivatives as PI3K inhibitors
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
AU2019407426A1 (en) 2018-12-21 2021-07-22 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
WO2020146237A1 (en) 2019-01-07 2020-07-16 Incyte Corporation Heteroaryl amide compounds as sting activators
TWI829857B (en) 2019-01-29 2024-01-21 美商英塞特公司 Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
CA3130210A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Cyclin-dependent kinase 2 biomarkers and uses thereof
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
EP3982971A4 (en) 2019-06-10 2023-08-16 Incyte Corporation Topical treatment of vitiligo by a jak inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2022543062A (en) 2019-08-01 2022-10-07 インサイト・コーポレイション Dosing Regimens for IDO Inhibitors
WO2021030537A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
KR20220066074A (en) 2019-08-26 2022-05-23 인사이트 코포레이션 Triazolopyrimidines as A2A/A2B inhibitors
US11839619B2 (en) 2019-09-16 2023-12-12 The Regents Of The University Of California Methods for treatment of pediatric systemic mastocytosis
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
MX2022004390A (en) 2019-10-11 2022-08-08 Incyte Corp Bicyclic amines as cdk2 inhibitors.
WO2021076602A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
JP7518900B2 (en) 2019-10-16 2024-07-18 インサイト・コーポレイション Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (LP) - Patent Application 20070233334
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN115697343A (en) 2020-03-06 2023-02-03 因赛特公司 Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
BR112022020841A2 (en) 2020-04-16 2023-05-02 Incyte Corp CAST TRICYCLIC KRAS INHIBITORS
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
HUE069125T2 (en) 2020-06-02 2025-02-28 Incyte Corp Processes of preparing a jak1 inhibitor
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022019998A1 (en) 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
WO2022047093A1 (en) 2020-08-28 2022-03-03 Incyte Corporation Vinyl imidazole compounds as inhibitors of kras
CN116261447A (en) 2020-09-16 2023-06-13 因赛特公司 Topical treatment of vitiligo
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
US11969420B2 (en) 2020-10-30 2024-04-30 Arog Pharmaceuticals, Inc. Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
WO2022090547A1 (en) 2020-10-30 2022-05-05 Dsm Ip Assets B.V. Production of carotenoids by fermentation
KR20230118118A (en) 2020-12-08 2023-08-10 인사이트 코포레이션 JAK1 pathway inhibitors for the treatment of vitiligo
WO2022155941A1 (en) 2021-01-25 2022-07-28 Qilu Regor Therapeutics Inc. Cdk2 inhibitors
CN115124551B (en) * 2021-03-24 2024-04-30 奥锐特药业(天津)有限公司 Preparation method of high-purity midostaurin
WO2022206888A1 (en) 2021-03-31 2022-10-06 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
TW202304459A (en) 2021-04-12 2023-02-01 美商英塞特公司 Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
US12268667B2 (en) 2021-05-03 2025-04-08 Incyte Corporation JAK1 pathway inhibitors for the treatment of prurigo nodularis
TW202313611A (en) 2021-06-09 2023-04-01 美商英塞特公司 Tricyclic heterocycles as fgfr inhibitors
EP4352060A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
WO2023283213A1 (en) 2021-07-07 2023-01-12 Incyte Corporation Tricyclic compounds as inhibitors of kras
JP2024529347A (en) 2021-07-14 2024-08-06 インサイト・コーポレイション Tricyclic Compounds as Inhibitors of KRAS
JP2024534187A (en) 2021-08-31 2024-09-18 インサイト・コーポレイション Naphthyridine Compounds as Inhibitors of KRAS - Patent application
US12030883B2 (en) 2021-09-21 2024-07-09 Incyte Corporation Hetero-tricyclic compounds as inhibitors of KRAS
EP4408536A1 (en) 2021-10-01 2024-08-07 Incyte Corporation Pyrazoloquinoline kras inhibitors
AU2022367432A1 (en) 2021-10-14 2024-05-02 Incyte Corporation Quinoline compounds as inhibitors of kras
CA3237696A1 (en) 2021-11-08 2023-05-11 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
TW202320792A (en) 2021-11-22 2023-06-01 美商英塞特公司 Combination therapy comprising an fgfr inhibitor and a kras inhibitor
WO2023102184A1 (en) 2021-12-03 2023-06-08 Incyte Corporation Bicyclic amine compounds as cdk12 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
AR128043A1 (en) 2021-12-22 2024-03-20 Incyte Corp SALTS AND SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR THEIR PREPARATION
WO2023168686A1 (en) 2022-03-11 2023-09-14 Qilu Regor Therapeutics Inc. Substituted cyclopentanes as cdk2 inhibitors
TW202341982A (en) 2021-12-24 2023-11-01 大陸商上海齊魯銳格醫藥研發有限公司 Cdk2 inhibitors and use thereof
EP4490151A1 (en) 2022-03-07 2025-01-15 Incyte Corporation Solid forms, salts, and processes of preparation of a cdk2 inhibitor
JP2025519705A (en) 2022-06-14 2025-06-26 インサイト・コーポレイション Solid forms of JAK inhibitors and processes for their preparation
CN114853784B (en) * 2022-06-16 2023-09-05 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) A staurosporine compound and its preparation method and application
WO2023250430A1 (en) 2022-06-22 2023-12-28 Incyte Corporation Bicyclic amine cdk12 inhibitors
US20240101557A1 (en) 2022-07-11 2024-03-28 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants
WO2024030600A1 (en) 2022-08-05 2024-02-08 Incyte Corporation Treatment of urticaria using jak inhibitors
US20240390340A1 (en) 2023-04-18 2024-11-28 Incyte Corporation Pyrrolidine kras inhibitors
TW202446371A (en) 2023-04-18 2024-12-01 美商英塞特公司 2-azabicyclo[2.2.1]heptane kras inhibitors
WO2024254245A1 (en) 2023-06-09 2024-12-12 Incyte Corporation Bicyclic amines as cdk2 inhibitors
WO2025096738A1 (en) 2023-11-01 2025-05-08 Incyte Corporation Kras inhibitors
WO2025129002A1 (en) 2023-12-13 2025-06-19 Incyte Corporation Bicyclooctane kras inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86632A0 (en) * 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
EP0383919A4 (en) * 1988-02-04 1992-08-05 Kyowa Hakko Kogyo Co., Ltd. Staurosporin derivatives
IL94274A0 (en) 1989-05-05 1991-03-10 Goedecke Ag Maleinimide derivatives,process for the preparation thereof and pharmaceutical compositions containing the same
WO1991009034A1 (en) 1989-12-14 1991-06-27 Schering Corporation Indolocarbazoles from saccharothrix aerocolonigenes subsp. copiosa subsp. nov. scc 1951 atcc 53856
US5658895A (en) * 1991-10-07 1997-08-19 Otsuka Pharmaceutical Factory, Inc. Anticancer enteral feeding composition
EP0540185A1 (en) 1991-10-10 1993-05-05 Schering Corporation 4'-(N-substituted-N-oxide)staurosporine derivatives
US5344926A (en) * 1992-06-22 1994-09-06 Kyowa Hakko Kogyo Co., Ltd. Process for producing staurosporine derivatives
CA2140661A1 (en) 1992-07-20 1994-02-03 Sharat Singh Novel chemiluminescent compounds and methods of use
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
AU678435B2 (en) 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
WO1995032976A1 (en) 1994-06-01 1995-12-07 Ciba-Geigy Ag Polycyclic lactam derivatives for sensitizing multidrug-resistant cells to antitumour agents
EP0711556A1 (en) 1994-11-09 1996-05-15 Ciba-Geigy Ag Intravenous solutions containing staurosporine derivatives
EP0733358A3 (en) * 1995-03-21 1998-05-20 Novartis AG Nanosuspensions for intravenous application
JPH09299092A (en) * 1996-03-12 1997-11-25 Takeda Chem Ind Ltd New protein and its dna
AU4205597A (en) * 1996-08-20 1998-03-06 Novartis Ag Methods for prevention of cellular proliferation and restenosis
CN1303985C (en) 1996-08-22 2007-03-14 Rtp药品公司 Compositions comprising microparticles of water-insoluble substances and method for preparing same
CO4940430A1 (en) * 1997-07-07 2000-07-24 Novartis Ag POLYCLIC COMPOUNDS CONTAINING HYDROGENATED STAUROSPORIN WITH CONVENIENT PHARMACOLOGICAL PROPERTIES AND AN INHIBITING EFFECT ON THE GROWTH OF TUMOR CELLS
AU1392299A (en) 1997-11-26 1999-06-15 Eli Lilly And Company Therapeutic treatment for chronic myeloid leukemia and acute lymphoid leukemia
WO2000011470A1 (en) 1998-08-20 2000-03-02 Chugai Seiyaku Kabushiki Kaisha Method for screening candidate compounds for drug against tumor
GB9903547D0 (en) 1999-02-16 1999-04-07 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US7973031B2 (en) 2011-07-05
AU2006249245B2 (en) 2009-11-05
BR0213739A (en) 2004-10-19
MXPA04004137A (en) 2005-01-25
WO2003037347A1 (en) 2003-05-08
KR20050040842A (en) 2005-05-03
KR20090087139A (en) 2009-08-14
CY1106199T1 (en) 2011-06-08
NZ532136A (en) 2006-08-31
CA2462657A1 (en) 2003-05-08
US8445479B2 (en) 2013-05-21
HUP0401642A2 (en) 2004-11-29
CN101703509A (en) 2010-05-12
HU230798B1 (en) 2018-06-28
NO20042123L (en) 2004-07-13
US20120252785A1 (en) 2012-10-04
HUP0401642A3 (en) 2008-05-28
US20110224194A1 (en) 2011-09-15
KR100926194B1 (en) 2009-11-09
CA2462657C (en) 2011-04-26
BRPI0213739B1 (en) 2020-06-09
NO335685B1 (en) 2015-01-19
IL161156A0 (en) 2004-08-31
RU2337692C2 (en) 2008-11-10
US8222244B2 (en) 2012-07-17
BRPI0213739B8 (en) 2021-05-25
US20050020570A1 (en) 2005-01-27
RU2337692C3 (en) 2020-11-09
RU2004116472A (en) 2005-05-10
DK1441737T3 (en) 2006-11-13
FR18C1012I1 (en) 2018-04-27
AU2006249245A1 (en) 2007-01-04
ATE335490T1 (en) 2006-09-15
FR18C1012I2 (en) 2021-06-11
PT1441737E (en) 2006-12-29
CN1582150B (en) 2011-09-07
JP2005507412A (en) 2005-03-17
EP1441737A1 (en) 2004-08-04
JP4959918B2 (en) 2012-06-27
CN1582150A (en) 2005-02-16
HK1068262A1 (en) 2005-04-29
DE60213842T2 (en) 2007-09-06
EP1441737B1 (en) 2006-08-09
DE60213842D1 (en) 2006-09-21
TWI302836B (en) 2008-11-11
PL211461B1 (en) 2012-05-31
IL161156A (en) 2011-02-28
TW200301127A (en) 2003-07-01
ES2269793T3 (en) 2007-04-01
ZA200402498B (en) 2005-07-27

Similar Documents

Publication Publication Date Title
IL161156A0 (en) Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
JO2764B1 (en) Indole derivatives or benzimidazole derivatives for modulating ikappab kinase
NZ543661A (en) Pyrazolo-quinazoline derivatives having antitumor activity and process for their preparation
WO1999057117A3 (en) Indole derivatives and their use in the treatment of malignant and other diseases caused by pathological cell proliferation
GB0022438D0 (en) Organic Compounds
JO2503B1 (en) Benzothiazole derivatives
MXPA03012013A (en) Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives as medicaments for the treatment of pain.
HUP0202186A3 (en) Benzimidazolone derivatives, process for their preparation, pharmaceutical compositions containing them and their use as phosphodiesterase inhibitors for producing pharmaceutical compositions
NO20024364D0 (en) Use of pyrido [3,2-E] pyrazinones as inhibitors of phosphodiesterase 5 for the treatment of erectile dysfunction
LU90569B1 (en) Articles of manufacture
MXPA04002714A (en) Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug.
MXPA05013200A (en) Staurosporine derivatives for hypereosinophilic syndrome.
WO2001051473A8 (en) 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation
GEP20105095B (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
PL1843771T3 (en) Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity
WO2002070515A3 (en) Chromane derivatives, process for their preparation and their use as antitumor agents
IL154755A0 (en) Antitumor theraphy comprising distamycin derivatives
AU2003258630A1 (en) Pyrimidine derivatives as selective cox-2 inhibitors
TR200302134T4 (en) Use of 2-methyl-thiazolidine-2,4-dicarboxylic acid and / or physiologically acceptable salts thereof as anti-cancer agents.
WO2004041244A3 (en) Oral extended release tablets and methods of making and using the same
IL160605A (en) Use of c2-substituted indan-1-ol systems for preparing medicaments for the prophylaxis or treatment of obesity
PT1474415E (en) 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, the use thereof for producing drugs used in the treatment of immunological diseases
WO2001056590A3 (en) Utilization of protein kinase inhibitor alpha
SI1441737T1 (en) Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity

Legal Events

Date Code Title Description
RECP Rectifications of patent specification